Evidence map›Paper›PMID 17261625›Full record

ArticleAntimicrobial agents and chemotherapy2007

Antistaphylococcal activity of DX-619 alone and in combination with vancomycin, teicoplanin, and linezolid assessed by time-kill synergy testing.

Kim Credito, Genrong Lin, Peter C Appelbaum

Abstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Kim CreditoDepartment of Pathology, Hershey Medical Center, P.O. Box 850, Hershey, PA 17033, USA.
Genrong Lin
Peter C Appelbaum

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Time-kill synergy studies testing in vitro activity of DX-619 alone and with added vancomycin, teicoplanin, or linezolid against 101 Staphylococcus aureus strains showed synergy between DX-619 and teicoplanin at 12 to 24 h in 72 strains and between DX-619 and vancomycin in 28 strains. No synergy was found with linezolid, and no antagonism was observed with any combination.

Indexed as

Drug SynergismAcetamidesAnti-Bacterial AgentsDrug Therapy, CombinationLinezolidMicrobial Sensitivity TestsOxazolidinonesPyrrolidinesQuinolonesStaphylococcus aureusTeicoplaninTime FactorsVancomycinAcetamidesAnti-Bacterial AgentsDX 619LinezolidOxazolidinonesPyrrolidinesQuinolonesTeicoplaninVancomycin

Identifiers

PMID17261625
PMCPMC1855475

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.